TITLE

[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease

AUTHOR(S)
Winogrodzka, A.; Bergmans, P.; Booij, J.; van Royen, E. A.; Janssen, A. G. M.; Wolters, E. Ch.
PUB. DATE
September 2001
SOURCE
Journal of Neural Transmission;Sep2001, Vol. 108 Issue 8/9, p1011
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary. We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43–73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [123I]FP-CIT binding to the striatum was used as the outcome measure. The mean annual decrease in striatal [123I]FP-CIT binding ratios was found to be about 8% (of the baseline mean). In order to demonstrate a significant effect (p < 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.
ACCESSION #
15394866

 

Related Articles

  • Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. Storch, A.; Ludolph, A. C.; Schwarz, J. // Journal of Neural Transmission;Oct2004, Vol. 111 Issue 10-11, p1267 

    The carrier molecule that transports dopamine (DA) into dopamine neurons by an electrogenic, Na+- and Cl--transport-coupled mechanism is known as the dopamine transporter (DAT). This uptake system is exclusively expressed in DA neurons with significantly higher levels of DAT expression in cells...

  • An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson’s disease. Song, In-Uk; Chung, Yong-An; Oh, Jin-Kyoung; Chung, Sung-Woo // Acta Radiologica;Apr2014, Vol. 55 Issue 3, p366 

    The article focuses on a study that compares FP-CIT PET which detects the differences in regional dopamine transporter (DAT) density in the brain in subtypes of early Parkinson's disease (PD). It mentions that there are differences in nigrostriatal dopaminergic dysfunction between the two PD...

  • Cell death in Parkinson's disease. Maruyama, Wakako; Naoi, Makoto // Journal of Neurology;Sep2002 Supplement 2, Vol. 249, pii06 

    The cause of neuronal cell death in Parkinson's disease is still an enigma. However, recent results obtained by analyses of postmortem brain suggest that a mitochondria-dependent apoptotic signal was activated. The involvement of dopamine-derived endogenous neurotoxin in the pathogenesis of PD...

  • Intrastriatal iron perfusion releases dopamine: an in-vivo microdialysis study. Prikhojan, A.; Brannan, T.; Yahr, M. D. // Journal of Neural Transmission;May2002, Vol. 109 Issue 5/6, p645 

    Summary. We perfused iron as FeCl3 directly into the striatum of normal rats and used the in vivo microdialysis technique to monitor striatal levels of dopamine (DA). KCl was perfused to assess the functional integrity of the DA receptors at the end of each dialysis experiment. Cu+2 (as CuSO4)...

  • Diabetic Gastroparesis in a Patient with Parkinson's Disease: Effective Treatment with Domperidone. Day, John P.; Pruitt, Ron E. // American Journal of Gastroenterology;Jul1989, Vol. 84 Issue 7, p837 

    Describes the case of a patient with Parkinson's disease in which central dopamine deficiency is characteristic. Medical history of the patient; Improvement in the condition of the patient following treatment with domperidone; Occurrence of neurological side effects with metoclopramide.

  • A channel to neurodegeneration. Deutch, Ariel Y.; Winder, Danny G. // Nature Medicine;Jan2006, Vol. 12 Issue 1, p17 

    The article determines the role of the differential vulnerability of dopamine cells in Parkinson disease. Neurons in certain brain regions of people suffering from the disease are more likely to die than others. Dysfunction of the mitochondrial electron transport chain increases in reactive...

  • Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area – model of the early beginning of Parkinson's symptomatology? Heim, C.; Sova, L.; Kurz, T.; Kolasiewicz, W.; Schwegler, H.; Sontag, K.-H. // Journal of Neural Transmission;May2002, Vol. 109 Issue 5/6, p691 

    Summary. To test substances which might have protective effects on the dopaminergic system it is necessary to use models with a pathological symptomatology of the early beginning, i.e. models in which the chance exists to arrest the otherwise progressive pathological processes (see Heim et al.,...

  • Parkin Promotes Degradation of the Mitochondrial Pro-Apoptotic ARTS Protein. Kemeny, Stav; Dery, Dikla; Loboda, Yelena; Rovner, Marshall; Lev, Tali; Zuri, Dotan; Finberg, John P. M.; Larisch, Sarit // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Parkinson's disease (PD) is associated with excessive cell death causing selective loss of dopaminergic neurons. Dysfunction of the Ubiquitin Proteasome System (UPS) is associated with the pathophysiology of PD. Mutations in Parkin which impair its E3-ligase activity play a major role in the...

  • QSAR AND DOCKING STUDIES OF APHORPHINE DERIVATIVES AS EFFICACIOUS PARTIAL ANTAGONISTS FOR PARKINSON'S DISEASE. BOLISETTY, VENKATESWARLU; K., NAGESWAR RAO; V., MANAIAH // International Journal of Pharma & Bio Sciences;Jan-Mar2014, Vol. 5 Issue 1, p465 

    Parkinson's disease is caused due to enhanced dopaminergic activity in the substantia nigra, a region of the midbrain. Dopamine Receptors are the main drugs used in the treatment of Parkinson's disease. In this work, docking studies have been performed in order to understand the interaction...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics